GlassScriptPhysician profile
Michael A Sanchez
NPI 1538329602
$2,530.22
in general payments reported to CMS, 2019-2025
26 companies · $455 in 2025
The $455 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.44 · 2020: $212 · 2021: $298 · 2022: $266 · 2023: $731 · 2024: $532 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,486 · Travel and Lodging: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.14 |
| Travel and Lodging | $231.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $409.65 | 2023-2024 | Da Vinci Surgical System |
| Ethicon INC. | $406.16 | 2020-2023 | Monarch Platform |
| Actelion Pharmaceuticals US, INC. | $271.36 | 2019-2025 | Uptravi |
| Merck Sharp & Dohme LLC | $208.15 | 2020-2024 | Winrevair, Keytruda |
| United Therapeutics Corporation | $131.33 | 2022-2025 | Tyvaso, Tyvaso |
| Alexion Pharmaceuticals, INC. | $121.83 | 2021 | |
| Baxter Healthcare | $95.96 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Abbvie INC. | $92.53 | 2021-2025 | Teflaro, Dalvance, Avycaz |
| Genzyme Corporation | $84.67 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $82.79 | 2022-2025 | Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $78.27 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.08 | 2019-2025 | Ofev |
| Grifols USA, LLC | $65.85 | 2024-2025 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $63.57 | 2021-2023 | |
| Insmed, INC. | $43.57 | 2025 | Arikayce, Brinsupri |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $42.67 | 2020 | |
| Tactile Systems Technology INC | $38.82 | 2023 | Flexitouch Plus, Entre Plus |
| Glaxosmithkline, LLC. | $34.47 | 2019-2023 | Trelegy Ellipta |
| Philips North America LLC | $31.10 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Viatris Specialty LLC | $28.54 | 2025 | Yupelri |
| Scpharmaceuticals INC. | $25.43 | 2024 | |
| Janssen Pharmaceuticals, INC | $22.84 | 2024 | Xarelto |
| Mylan Specialty L.P. | $20.51 | 2023 | Yupelri |
| Verona Pharma, INC. | $18.21 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $18.00 | 2024 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $17.86 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.